Applications
Online Inquiry
For research use only. Not intended for any clinical use.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Non-Human Primate (NHP) Application in HIV, SARS-CoV-2, Emerging Viruses
Are you currently facing high data variability, long development cycles, and challenges in replicating complex human immune responses? Our Creative Biolabs Integrated Precision Platform helps you streamline and de-risk infectious disease pipelines through genetically defined NHP cohorts, advanced delivery techniques, and comprehensive, multi-omics bioanalysis.
NHP Models Drive High-Fidelity Translational Data and Accelerate Your Preclinical Path!
Validating multi-modal therapies for complex viruses requires high-fidelity NHP models. Creative Biolabs controls immunogenetics and dosing precision to deliver the translational certainty needed for IND submission.
Overview of NHP Applications
What Are Our Research Areas?
The field of infectious disease research has rapidly transitioned toward complex, curative strategies, moving beyond standard antiviral treatments. This requires sophisticated in vivo systems to model the complete disease spectrum, from primary infection and latency establishment to rapid immune evasion. Success hinges on accurately assessing the safety, biodistribution, and long-term efficacy of next-generation modalities, including broadly neutralizing antibodies, and AAV vectors designed for sustained therapeutic expression.
Why Choose Us?
NHPs are the gold standard for translational infectious disease studies due to their distinct biological and regulatory advantages. Creative Biolabs leverages these advantages while rigorously controlling variability:
- Genetic/Immunological Similarities: NHPs possess close homology in MHC and innate immune proteins that govern host-pathogen interaction, allowing for high-fidelity modeling of human immune responses.
- Clinical Translational Relevance: NHP data on safety, toxicology, and immunogenicity are the most highly regarded by regulatory bodies for predicting human outcomes, particularly for novel modalities like gene and cell therapies.
- Assessment of Anatomical Reservoirs: Unlike human clinical studies, NHP models permit the collection and analysis of tissues critical to viral persistence (lymph nodes, GI tract, spleen), providing a complete picture of therapeutic impact.
- Controlled Testing Environment: They allow for the ethical, controlled evaluation of complex variables, including viral dose, route of exposure, timing of ART initiation, and simultaneous assessment of safety and efficacy for multi-modal cures.
Fig.1 Illustration of key NHP species utilized for assessing various facets of SARS-CoV-2 biology.1
Key Applications
Creative Biolabs provides specialized NHP models to answer the most pressing translational questions in infectious disease research:
- Modeling Latency Reversal and Viral Reservoir Elimination: NHP models are used to define the efficacy of "Shock-and-Kill" or "Block-and-Lock" cure strategies. This includes testing latency reversal agents for provirus reactivation and assessing the effect of immunotherapies on eliminating the reactivated, infected cells in peripheral blood and tissue reservoirs.
- Vector Biodistribution and Safety for Gene Therapies: NHPs are required for preclinical validation of AAV-delivered broadly neutralizing antibodies or gene edits. Studies precisely quantify vector copy number and shedding in various tissues, providing essential data on dose safety, persistence, and non-target risk required for IND submission.
- Vaccine Efficacy and Passive Immunization Studies: NHP challenge models are critical for measuring vaccine-induced protection and the in vivo efficacy of passively transferred broad and potent neutralizing antibodies against emerging or chronic viruses (HIV, SARS-CoV-2). This includes monitoring the development of neutralizing antibody titers and ADCC activity.
- Host Immunogenetics and Pathogenesis Correlation: NHPs are used to correlate specific host genetic profiles with disease progression. By stratifying cohorts based on these immune factors, researchers can isolate and validate therapeutic mechanisms against defined biological backgrounds, significantly reducing data variability caused by host noise.
How Do Creative Biolabs Support Your Projects?
Creative Biolabs offers specialized, keyword-rich services to ensure scientific rigor and maximize lead generation for our clients. Below are key capabilities relevant to NHP-based infectious disease and advanced therapy research:
| Service Capability | Corresponding Application Area |
| NHP Bio-specimen Bank | Provides isolated immune cells critical for latent reservoir quantification (e.g., CD4+ T cell isolation) and ex vivo functional assays. |
| In Vivo PK Studies | Tracks the systemic exposure and anatomical distribution of viral vectors (AAV) and advanced biologics over time in key reservoir tissues. |
| In Vitro Cell-Based Safety Assays | Utilizes primary NHP immune cells to assess the potential for systemic toxicity, such as cytokine storm, from T-cell engagers or advanced therapies. |
| PK/TK Sample Analysis | High-resolution quantification of the vector genome in minute tissue samples and body fluids, essential for safety assessment and shedding studies. |
Translational Impact
The primary goal of NHP infectious disease research is to generate data that is predictive of human clinical outcomes and satisfies regulatory requirements.
- Early Detection of Immune Responses/Toxicity: By utilizing our specialized in vitro NHP cell-based assays alongside in vivo monitoring, we can detect inflammatory and immunotoxicity signals far earlier than conventional studies, allowing for critical protocol adjustments.
- Reduced Risk of IND Failure: NHP biodistribution and shedding data for AAV vectors, along with comprehensive safety and immunogenicity profiles, are often required for gene therapy IND submissions. We deliver this data package with the necessary scientific rigor and detail.
Frequently Asked Questions
Q: How does Creative Biolabs address the high biological variability commonly seen in NHP infectious disease models?
A: We manage variability through rigorous control of both biological and operational factors. Biologically, we offer Donor-Matched Cohorts and perform genetic stratification, screening for critical immunogenetic markers. This ensures your cohorts are tightly defined, allowing us to attribute observed outcomes directly to your therapeutic agent rather than random host differences.
Q: What is the resolution and sensitivity for measuring AAV vector delivery and shedding in key anatomical reservoirs?
A: We utilize highly sensitive techniques, including qPCR and ddPCR, to determine Vector Copy Number. Our specialized tissue processing protocols ensure accurate and high-resolution quantification in complex matrices like lymphoid tissues, CSF, and GI tract biopsies, meeting strict regulatory requirements for biodistribution studies.
Q: Can we obtain specific immune cell populations to accurately study the latent HIV reservoir size and dynamics?
A: Absolutely. Our Bio-specimen Bank and Custom Collection Services include advanced processing of PBMCs, as well as specialized techniques for isolating target cells from peripheral blood and critical lymphoid tissues. This provides the necessary cellular substrate for downstream assays.
Q: What logistical support is available for multi-center or long-term infectious disease studies involving NHP bio-samples?
A: We offer end-to-end support through our Full-Service Sample Management, including customized Longitudinal & Repeat Sampling schedules, controlled Cold-Chain Transportation, and comprehensive Bioanalysis & Biomarker profiling. We ensure sample integrity from collection to final data report, streamlining your multi-year preclinical timeline.
Contact Us
Creative Biolabs empowers infectious disease research by systematically eliminating the biological and operational noise that hinders therapeutic development. By integrating genetically defined cohorts with precision delivery and advanced bioanalytical services, we ensure that your data is scientifically sound and regulatory-ready. To learn more about how Creative Biolabs can apply the Integrated Precision Platform to your specific HIV, SARS-CoV-2, or Emerging Virus program, please reach out to our team of expert biologists and program managers.
Reference
- Berry, Neil, et al. "The impact and effects of host immunogenetics on infectious disease studies using non-human primates in biomedical research." Microorganisms 12.1 (2024): 155. Distributed under Open Access license CC BY 4.0, without modification. DOI: https://doi.org/10.3390/microorganisms12010155